Psoriasis is a chronic autoimmune skin disorder characterized by red, scaly patches that affect the skin, scalp, and joints. According to a study published in 2025, the global prevalence of psoriasis stands at 4.4%. It accounts for a significant portion of dermatological conditions, driving demand for better therapies. The growing focus on biologics, immunomodulators, and personalized treatments is shaping the future of psoriasis therapeutics. Recent advancements, including targeted biologic drugs, are expected to boost pipeline growth. The psoriasis pipeline analysis by Expert Market Research highlights promising drug candidates under development, signaling strong potential for innovation in the coming years.
Major companies involved in the psoriasis pipeline analysis include Bausch Health Americas, Inc., Bristol-Myers Squibb, and others.
Leading drugs currently in the pipeline include HS-10374, LY3972406, SFA002, and others.
The growth of the pipeline is driven by increasing cases of moderate to severe psoriasis, advancements in immune pathway targeting, and strong clinical trial activity supported by regulatory incentives for innovative treatments.
The Psoriasis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into psoriasis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for psoriasis. The psoriasis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The psoriasis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with psoriasis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to psoriasis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Psoriasis is a chronic, immune-mediated skin disorder characterized by red, scaly plaques that typically appear on the elbows, knees, scalp, and lower back. It occurs due to an accelerated skin cell turnover triggered by immune system dysfunction, particularly involving T-cells and cytokines like interleukin-17 and interleukin-23. Genetic and environmental factors also contribute to its onset and severity.
Psoriasis treatment includes topical agents, phototherapy, systemic medications, and biologic therapies. These medications target immune responses and reduce inflammation, helping to control flare-ups and improve the patient’s quality of life. For instance, Bimekizumab, an FDA-approved dual IL-17A/F inhibitor, emerged as a promising treatment for moderate to severe psoriasis by simultaneously targeting both key inflammatory cytokines, offering enhanced clinical efficacy.
Recent epidemiological studies indicate a global psoriasis prevalence of 4.4%. Europe reports similar rates at 4.6%, while Asia shows a higher prevalence of 5.7%. In contrast, Latin America reports 3.1%, Africa 1.7%, and North America 3.7%. The Middle East records 4.9%. Urban areas have a higher prevalence of 4.8% compared to 3.8% in semi-urban and 4.3% in rural areas. Fair-skinned individuals show a slightly higher prevalence than dark-skinned individuals.
This section of the report covers the analysis of psoriasis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III holds the largest share in the psoriasis drug pipeline at 42.78%, reflecting strong advancements toward late-stage development. Phase IV accounts for 23.71%, while Phase II represents 19.07%. Phase I contributes 12.37%, and the early phase I covers 2.06%. This balanced pipeline highlights consistent innovation and promises a positive impact on future psoriasis treatment options and market growth.
The drug molecule categories covered under the psoriasis pipeline analysis include small molecules, monoclonal antibodies, topical agents, RNA-based therapies, natural products & botanical extracts, and others. The psoriasis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for psoriasis.
Phosphodiesterase-4 (PDE4) inhibitors are gaining momentum in the psoriasis drug pipeline. For example, Arcutis Biotherapeutics’ investigational drug Zoryve (roflumilast) foam 0.3% targets scalp and body psoriasis in individuals aged 12 and older. Supported by strong Phase 2b and Phase 3 trial data, this once-daily topical therapy has shown significant efficacy, particularly in hard-to-treat scalp psoriasis, and is currently under review by the United States Food and Drug Administration.
The EMR report for the psoriasis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed psoriasis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in psoriasis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for psoriasis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of psoriasis drug candidates.
HS-10374, developed by Hansoh BioMedical R&D Company, is a novel, highly selective allosteric TYK2 inhibitor targeting IL-12 and IL-23 signaling, key cytokines in psoriasis. It is undergoing Phase III clinical development where it is being evaluated for its efficacy and safety in adults with moderate to severe plaque psoriasis. The trial is running over 52 weeks and aims to confirm its therapeutic potential and tolerability.
LY3972406, sponsored by Eli Lilly and Company, is a part of a Phase II clinical trial to evaluate its efficacy and safety in adults with moderate-to-severe plaque psoriasis. The study investigates how LY3972406, an orally administered Kv1.3 inhibitor, works to modulate immune responses in autoimmune diseases, including psoriasis. The trial is currently enrolling an estimated 75 participants.
SFA-002, backed by SFA Therapeutics, is currently undergoing a Phase I clinical study to evaluate its safety, metabolism, and efficacy in patients with mild to moderate chronic plaque psoriasis. This oral immunomodulator targets multiple inflammatory cytokines simultaneously. The study is enrolling 90 participants and is focusing on assessing both short-term and residual therapeutic effects.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Psoriasis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for psoriasis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the psoriasis pipeline insights.
Psoriasis Epidemiology Forecast
Plaque Psoriasis Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share